TVG Announces Merck, AstraZeneca, Pfizer, GSK, Novartis, BMS, Roche, Takeda, Amgen, and Genzyme Are Looking for Deals at t

LONDON--(BUSINESS WIRE)-- Technology Vision Group (TVG) is pleased to announce that the leaders of the pharmaceutical industry will gather in London on 10-12 October 2010 in pursuit of partnering opportunities with biotechnology companies at the 18th Annual BioPartnering Europe conference.

Two of the top decision-makers in the pharmaceutical industry will speak: Dr. David Nicholson, Senior Vice President, Worldwide Licensing and Knowledge Management, Merck & Co., Inc., and Dr. Anders Ekblom, Executive Vice President, Global Medicines Development at AstraZeneca.

"Pharma is already executing on transformational strategies that are defining the future of the life science industry. BPE is a catalyst for that transformation – bringing together the power players who are driving change, forging new alliances in new markets, and redefining how business is done. BPE is not just an event, it is a critical strategic moment for industry leaders focused on advancing their pipeline and pursuing partnerships." - Dr. Robert Lee Kilpatrick, Partner, TVG

Learn more about Merck’s Licensing areas of interest
http://www.merck.com/licensing/areas-of-interest/home.html

Review AstraZeneca’s partnering strategy
http://www.astrazeneca.com/partnering/

Conference delegates will have the opportunity to meet face-to-face to discuss partnering, business strategy, and the changing pharmaceutical market with the top pharma leaders including Merck, AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb, Roche, Genzyme, Takeda, and Amgen.

About BioPartnering Europe

BioPartnering Europe™ (BPE) is Europe's longest-running life science partnering event and is a "must attend" event for decision-makers across the globe. BPE facilitates partnering, business development, investment efforts and face-to-face meetings supported by the biopartnering.com online network. BPE annually attracts 1,200 delegates from over 30 countries. For more information visit www.techvision.com/bpe.

About Technology Vision Group (TVG)

TVG is a life science networking company that is built on industry expertise and long-standing relationships. TVG provides clients with the connections, the venues, and the access needed to succeed in a global life science world. Since 1992, TVG has connected innovators and leaders in the life science industry across North America, Europe and Asia. TVG facilitates a global network that supports life science companies as they build new relationships, enter new markets, and create new products. For more information visit http://www.techvision.com.

Producer

TVG

2010 Podium Presenters and Exhibitors (As of August 11, 2010)

Adaptimmune Ltd.; Allostera Pharma Inc.; Amarantus Therapeutics, Inc.; Ambit Biosciences Corporation; AngioChem Inc.; Avantium Technologies B.V.; AWEX- Wallonia Foreign Trade & Investment Agency; BigDNA Limited; Bioalliance Pharma S.A.; Biothera; Calistoga Pharmaceuticals, Inc.; Can-Fite Technologies Ltd.; Catalent Pharma Solutions, Inc.; Celator Pharmaceuticals, Inc.; Cerenis Therapeutics; Champions Biotechnology, Inc.; Covagen AG; Crescendo Biologics Ltd.; Curis, Inc.; Current Partnering; Cytovance Biologics, Inc.; Debiopharm S.A.; Delphi Genetics; Emerald Biostructures; Fate Therapeutics Inc.; Flamel Technologies S.A.; Genfit; GENTICEL; ImmunoVaccine Inc.; INAGEN ApS; iPierian, Inc.; IXO Ltd.; Mirna Therapeutics Inc.; Mithridion Inc; mondoBIOTECH AG; MorphoSys AG; Movetis NV; NexMed, Inc.; Nuon Therapeutics Inc.; Oval Medical Technologies Limited; Oxford BioMedica plc; Pergamum AB; Plant Advanced Technologies; PolyMedix Inc.; PRUDENTAS LLC; PTC Therapeutics Inc.; Receptor Therapeutics Inc.; Receptos, Inc.; Rexahn Pharmaceuticals Inc.; RXi Pharmaceuticals Inc.; Scil Proteins GmbH; Somnus Therapeutics Inc.; Stabilitech Ltd.; SuperGen Inc.; Syndax Pharmaceuticals, Inc.; Tarix Pharmaceuticals; Telormedix SA; Tetraphase Pharmaceuticals; Tranzyme Pharma, Inc.; ADIS – Wolters Kluwer; YM BioSciences Inc.; ZS Pharma, Inc.

Sponsors

Platinum

AstraZeneca; Deloitte & Touche LLP

Gold

Amgen; Bristol-Myers Squibb Company; Ferghana Partners Group; Goodwin Procter; Ironwood Pharmaceuticals; Merck & Co., Inc.; Novartis; Pfizer; Roche; Takeda

Silver

Cooley Godward Kronish LLP; GlaxoSmithKline

Conference Sponsors

Central European Cooperative Oncology Group (CECOG); Genzyme; Nature Publishing Group

Conference Supporters

AusBiotech; General Biologic

Media Sponsors

Business Wire; Innovaro Pharmalicensing

Media Supporters

BioCentury; BIOCOM; BioWorld Today; Current Partnering; EBR; eChinaBio; European Life Science; goBalto; GoingPublic; Life Science Clusters; Life Sciences Lab; Nordic Life Science; PharmaVoice; Seeking Alpha; The Scientist

Regional Affiliates

Portuguese Bioindustries Association (APBio); BayBio; ByHelix; BioIndustry Association (BIA); BioAlberta; BioFlorida; BioMelbourne; Biominas Brasil; BIOTECanada; Colorado BioScience Association; European Federation of Biotechnology (EFB); LifeSciences British Columbia (LSBC); Netherlands Biotech Industry Association (NIABA); One Nucleus; Queensland Clinical Trials Network (QCTN); Swiss Biotech Association (SBA).

For more information regarding TVG and Your Global Life Science Network™, please visit: http://www.techvision.com/



CONTACT:

Technology Vision Group LLC
Rebecca Angelos, Operations & Conference Director
Tel: +1.831.464.4230 x153
Email: [email protected]
or
Presenter Sales
Technology Vision Group LLC
Elena Kogan, Director, Business Relations
Tel: +1.831.464.4230 x 137
Email: [email protected]
or
Media
Citigate Dewe Rogerson
Helena Galilee/Amber Bielecka
Tel: +44 (0)207.282.1052 / +44(0).207.216.4710
Email: [email protected] / [email protected]

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.